Study #2016-1101
A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Study Status
Open
Treatment Agent
BL-8040, Nelarabine
Principal Investigator
Tapan Kadia
Description
The goal of this clinical research study is to learn if the combination of BL-8040 and nelarabine is safe to give to patients with T-acute lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LBL) that is either relapsed (has come back after treatment) or refractory (has not responded to treatment). Researchers also want to learn if the drug combination can help to control either or both diseases.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: BL-8040, Nelarabine
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: BioLineRx, Ltd.,NIH,Washington University School of Medicine
Study Status
IRB Review and Approval Date: 09/25/2017
Recruitment Status: Open
Projected Accrual: 20
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789